Search

The aim of the study was the evaluation of the participation of fibrinolytic system in the pathogenesis of haemostasis disturbances on the base of the determination of plasminogenesis intensity and some other fibrinolytic parameters. The study was performed in the group of 73 patients suffering from chronic meyloproliferative syndromes aged 36-78 (means 54,0) years: in 22 with chronic myelogenous leukemia (CML), in 25 with polycythemia vera (PV), in 21 with essential thrombocythemia (ET) and in 5 patients with meylofibrosis (MF). Control group contained 30 healthy volunteers sex and age matched. In the citric plasma obtained from venous blood concentration of plasmin-alpha2 antiplasmin complexes (PAP) using immunosorbed method (ELISA), alpha-2-antiplasmin with chromogenic method, concentration of fibrinogen and fibrin/ /fibrinogen degradation products (FDP) were determined. In blood plasma of patients with chronic myeloproliferative syndromes increased concentration of PAP complexes was detected what is the evidence of high intensity of plasmin generation. more...

Serum concentration of aminoterminal peptide of type III procollagen (PIIINP) were determined in 48 patients with myeloproliferative disorders (MPD). 27 with and 21 without marrow fibrosis. Serum concentration of PIIINP in MPD was significantly higher than that in control group, but not in secondary thrombocytosis. The highest serum level of PIIINP was found in the primary osteomielofibrosis. In myeloproliferative disorder a positive correlation between megakaryocyte count, marrow fibrosis and serum level of PIIINP was found. This indicates, that in MPD megakaryocytes stimulates fibroblasts to augment their fibrile formation function. Concentration of PIIINP in the serum seems to be a good, though not specific, marker of marrow fibrosis in myeloproliferative disorders. more...

In 6 women aged 38 to 68 years with thrombocythaemia during chronic myeloid leukaemia (4 cases), myelofibrosis (1 case), and idiopathic thrombocythaemia (1 case) the effects of recombinant human alpha-interferon (Intron A, rh IFN alpha -2b, Schering) were studied. The drug was given to all patients subcutaneously in one daily dose of 3 x 10(6) u, every day for 3 weeks, and then in the same doses twice weekly for 2 weeks (5 cases) and for 14 weeks (1 case). Intron A caused in all cases a fall of peripheral blood platelet count by 37% to 65.5% (mean 50%) in relation to the initial count (532 - 1,453 x 10(9)/l). The fall of the platelet count occurred usually after 7-10 days of this treatment, and the lowest count was noted usually after 24 days (10 to 42 days). During the treatment in 4 cases the peripheral leucocyte count dropped as well by 20-70%. In no cases exacerbation of chronic myeloid leukaemia was noted, and in the patient with myelofibrosis the enlarged spleen shrunk somewhat. These results of treatment and follow-up of patients with thrombocythaemia treated with Intron A indicate a significant although short-lasting effect of platelet count fall limited, however, to the time of the treatment. Side effects of the drug included mainly febrile conditions, myalgia and arthralgia. more...

The activity of alkaline phosphatase and peroxidase was measured in polymorphonuclears in 20 cases of myelodysplasia syndromes, 10 cases of chronic myeloid leukaemia. Reduced phosphatase activity was found in 5 cases and peroxidase activity in 3 cases of myelodysplasia syndromes. No evident correlation was noted between the activity of these enzymes and prognosis. Increased proportion of peroxidase-negative granulocytes was observed, moreover, in most cases of chronic myeloid leukaemia. The observations will be continued in larger material. more...